Student research committee, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
BMC Cardiovasc Disord. 2024 Oct 9;24(1):545. doi: 10.1186/s12872-024-04223-0.
Glucomannan has been studied for various health benefits, but its effects on lipid profile in adults are not well understood. This meta-analysis aims to evaluate the impact of glucomannan supplementation on serum/plasma levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), Apo B1, Apo A1, APO-B/ A1 ratio, and LDL-C/ HDL-C in adults.
A comprehensive search was conducted across Scopus, PubMed, Embase, and Web of Science from inception to June 2024 to identify randomized controlled trials (RCTs) assessing glucomannan supplementation on lipid profile in adults. Data were extracted and analyzed using random effects model to determine the standardized mean differences (SMDs) and 95% confidence intervals (CIs) for each biomarker.
Glucomannan supplementation significantly decreased TC (SMD: -3.299; 95% CI: -4.955, -1.664, P < 0.001; I = 95.41%, P-heterogeneity < 0.001), LDL-C (SMD: -2.993; 95% CI: -4.958, -1.028; P = 0.006; I = 95.49%, P-heterogeneity < 0.001), and Apo B1 (SMD: -2.2; 95% CI: -3.58, -0.82; P = 0.01). However, glucomannan did not alter the levels of TG (SMD: -0.119; 95% CI: -1.076, 0.837, P = 0.789; I = 91.63%, P-heterogeneity < 0.001), Apo A1 (SMD: -0.48; 95% CI: -6.27, 5.32; P = 0.76), APO-B/ A1 ratio (SMD: -1.15; 95% CI: -2.91, 0.61; P = 0.11), and LDL-C/ HDL-C ratio (SMD: -2.2; 95% CI: -7.28, 2.87; P = 0.2).
Glucomannan supplementation has a beneficial effect on the level of TC and LDL-C.
葡甘露聚糖在各种健康益处方面已得到研究,但它对成年人血脂谱的影响尚未得到很好的理解。本荟萃分析旨在评估葡甘露聚糖补充剂对成年人血清/血浆总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、载脂蛋白 B1(Apo B1)、载脂蛋白 A1(Apo A1)、载脂蛋白 B/A1 比值和 LDL-C/HDL-C 的影响。
从成立到 2024 年 6 月,我们在 Scopus、PubMed、Embase 和 Web of Science 上进行了全面搜索,以确定评估葡甘露聚糖补充剂对成年人血脂谱影响的随机对照试验(RCT)。使用随机效应模型提取和分析数据,以确定每个生物标志物的标准化均数差(SMD)和 95%置信区间(CI)。
葡甘露聚糖补充剂显著降低了 TC(SMD:-3.299;95%CI:-4.955,-1.664,P<0.001;I²=95.41%,P 异质性<0.001)、LDL-C(SMD:-2.993;95%CI:-4.958,-1.028;P=0.006;I²=95.49%,P 异质性<0.001)和 Apo B1(SMD:-2.2;95%CI:-3.58,-0.82;P=0.01)。然而,葡甘露聚糖并没有改变 TG(SMD:-0.119;95%CI:-1.076,0.837,P=0.789;I²=91.63%,P 异质性<0.001)、Apo A1(SMD:-0.48;95%CI:-6.27,5.32;P=0.76)、APO-B/A1 比值(SMD:-1.15;95%CI:-2.91,0.61;P=0.11)和 LDL-C/HDL-C 比值(SMD:-2.2;95%CI:-7.28,2.87;P=0.2)的水平。
葡甘露聚糖补充剂对 TC 和 LDL-C 水平有有益的影响。